• Skip to main content

Hearing Loss Treatment Report

www.HearingLossTreatmentReport.com

News

FX-322 Phase 2a Clinical Trial Update: 4 new recruitment sites… plus, changes to eligibility criteria…

February 4, 2020

Frequency Therapeutics updates official Study Record of Phase 2a clinical trial, FX-322 in Adults With Stable Sensorineural Hearing Loss.

The changes were posted to ClinicalTrials.gov on January 29, 2020 and involve: a) four new study locations, and b) adjustments to the eligibility criteria.

Interestingly, the opening of any additional U.S. sites could add new information to a past statement made by Frequency Therapeutics Chief Executive Officer, David Lucchino, who said, “We have opened all U.S. sites for our Phase 2a study of FX-322,” according to a November 18, 2019 press release.

More importantly, however, is the great opportunity these new locations could provide to any interested (and eligible) patients living in New York, Texas, Utah, or Virginia.

Clinical Trial Recruitment Locations: EXTENDED EDITION

The following four locations were added to the list of clinical trial sites:

United States, New York
Amherst, New York, United States, 14226

United States, Texas
San Antonio, Texas, United States, 78258

United States, Utah
Salt Lake City, Utah, United States, 84102

United States, Virginia
Richmond, Virginia, United States, 23235

As of February 4, 2020, these four new locations are not yet recruiting patients. However, that could change at any moment. Meanwhile, the other recruitment sites — which were posted back in October — are still actively recruiting.

The other recent changes to the FX-322 clinical trial record involve the study’s Eligibility Criteria. Changes were made to both the Inclusion and Exclusion criteria.

FX-322 Trial Eligibility: REMASTERED

Inclusion Criteria (Nov 2019 vs. Feb 2020)

BEFORE:
Established diagnosis of sensorineural hearing loss by standard audiometric measures that is stable for ≥ 6 months prior to the Screening Visit [no changes greater than 5 decibels (dB) in anyfrequency].

AFTER:
Established diagnosis of stable sensorineural hearing loss by standard audiometric measures for ≥ 6 months prior to the Screening visit (no changes in air conduction greater than 10 dB at a singlefrequency or greater than 5 dB at two contiguous frequencies from the prior audiogram to the Screening audiogram in the study ear).

Exclusion Criteria (Nov 2019 vs. Feb 2020)

BEFORE:
Any conductive hearing loss of 10 dB or more at two or more frequencies in either ear.

AFTER:
Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10 dB at two or more contiguous octave frequencies in the study ear at the Screening visit or on the prior audiogram (if the Investigator feels there is not a true conductive hearing loss, the Medical Monitor should be consulted).

That’s all for now.

Note: The next actually interesting FX-322 progress update should be arriving in June, which is when Frequency Therapeutics could be ready to report top-line data from the trial.


Want more exclusive hearing loss treatment-related updates? Then you should subscribe to the free email newsletter.

Looking for updates for other related conditions? Check out these other “Treatment Report” pages: Tinnitus, Meniere’s Disease, and Hyperacusis.

Questions, comments, concerns, feedback? Email michael@urgentresearch.com and say hello.

Boston area startups making progress in fight against hearing loss

February 2, 2020

https://www.bostonglobe.com/2020/02/02/metro/boston-area-startups-making-slow-progress-fight-against-hearing-loss/

Boston area startups making slow progress in fight against hearing loss

Action on Hearing Loss and Medicines Discovery Catapult team up to launch new “Hearing Medicines Discovery Syndicate”, a collaboration designed to accelerate the “much-needed development” of treatments for hearing loss and tinnitus

January 10, 2020

http://www.pharmatimes.com/news/new_fast-track_system_for_tinnitus_and_hearing_loss_1321998

New ‘fast-track’ system for tinnitus and hearing loss

Action on Hearing Loss and the Medicines Discovery Catapult have teamed up to launch a new “Hearing Medicines Discovery Syndicate”, a collaboration designed to accelerate the “much-needed development” of treatments for hearing loss and tinnitus.

The collaboration will be partnering with the National Institute for Health Research (NIHR), with academic expertise in hearing research provided University College London Hospitals BRC, Nottingham BRC and Manchester BRC, and the Cell and Gene Therapy Catapult.

Sensorion Announces €5.6m Non-Dilutive Funding to Support SENS-401 Phase 2 Study in Sudden Sensorineural Hearing Loss; French Ministry of Armed Forces to Participate in the Study

December 23, 2019

https://www.businesswire.com/news/home/20191222005022/en/

https://www.biospace.com/article/releases/sensorion-announces-5-6m-non-dilutive-funding-to-support-sens-401-phase-2-study-in-sudden-sensorineural-hearing-loss-french-ministry-of-armed-forces-to-participate-in-the-study/

Sensorion Announces €5.6m Non-Dilutive Funding to Support SENS-401 Phase 2 Study in Sudden Sensorineural Hearing Loss; French Ministry of Armed Forces to Participate in the Study

Pipeline Therapeutics Completes $30 Million Series B Financing – Proceeds to advance PIPE-505 in hearing loss

December 18, 2019

https://www.businesswire.com/news/home/20191218005137/en/Pipeline-Therapeutics-Completes-30-Million-Series-Financing

Pipeline Therapeutics’ lead candidate, PIPE-505, is entering Phase 1b/2a testing to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. PIPE-505 is uniquely positioned to treat this patient population as it can have an impact on both audibility and speech intelligibility, addressing two separate pathologies associated with hearing loss.

Pipeline Therapeutics Completes $30 Million Series B Financing – Proceeds to advance PIPE-505 in hearing loss

Reprogramming inner ear to regrow hair cells promising target for hearing loss treatments

December 4, 2019

https://medicalxpress.com/news/2019-12-reprogramming-ear-regrow-hair-cells.html

DECEMBER 4, 2019

Reprogramming inner ear to regrow hair cells promising target for hearing loss treatments
by Massachusetts Eye and Ear Infirmary

3D-Printed Microneedles Open Ears to New Treatments

December 3, 2019

https://www.cuimc.columbia.edu/news/3d-printed-microneedles-open-ears-new-treatments

3D-Printed Microneedles Open Ears to New Treatments

SENS-401 shows capacity to reduce central auditory neuron loss after acoustic trauma in preclinical studies

November 7, 2019

https://www.businesswire.com/news/home/20191106005839/en/Sensorion-Announces-Oral-Presentation-New-SENS-401-Preclinical/

Sensorion Announces an Oral Presentation of New SENS-401 Preclinical Data at ISIET 2019 in Hannover: An oral presentation on the capacity of SENS-401 to reduce central auditory neuron loss after acoustic trauma in preclinical studies

SENS-401 shows capacity to reduce central auditory neuron loss after acoustic trauma in preclinical studies

New therapy has potential to repair cells damaged by noise, prevent hearing loss

November 6, 2019

https://www.news-medical.net/news/20191106/New-therapy-has-potential-to-repair-cells-damaged-by-noise-prevent-hearing-loss.aspx

New therapy has potential to repair cells damaged by noise, prevent hearing loss

Targeting the Inner Ear: New startups are taking aim at delivering drugs to help treat hearing loss

October 29, 2019

Targeting the Inner Ear

Targeting the Inner Ear
New startups are taking aim at delivering drugs to help treat hearing loss

Sensorion Announces a Poster Presentation of New SENS-401 Preclinical Data at SFN 2019 in Chicago

October 23, 2019

https://www.businesswire.com/news/home/20191022006061/en/Sensorion-Announces-Poster-Presentation-New-SENS-401-Preclinical

Sensorion Announces a Poster Presentation of New SENS-401 Preclinical Data at SFN 2019 in Chicago

A poster presentation on the absence of impact due to acoustic trauma on the SENS-401 inner ear exposure in preclinical studies

Sensorion Announces a Poster Presentation of New SENS-401 Preclinical Data at SFN 2019 in Chicago
A poster presentation on the absence of impact due to acoustic trauma on the SENS-401 inner ear exposure in preclinical studies

UPDATE: Frequency Therapeutics Expands List of FX-322 Clinical Trial Locations…

October 19, 2019

The phase 2a study of FX-322 in Adults With Stable Sensorineural Hearing Loss is now recruiting at 12 locations in 8 different states.

Previously, the only clinical trial location listed on the study page was in North Carolina. Not anymore…

Here is the expanded list featuring 11 new locations in 7 other states:

List of FX-322 Phase 2a Clinical Trial Locations

  1. Fresno, California, United States, 93720
  2. Torrance, California, United States, 90503
  3. Colorado Springs, Colorado, United States, 80909
  4. Boca Raton, Florida, United States, 33487
  5. Sarasota, Florida, United States, 34239
  6. Tampa, Florida, United States, 33612
  7. Louisville, Kentucky, United States, 40207
  8. Omaha, Nebraska, United States, 68118
  9. Durham, North Carolina, United States, 27713
  10. Winston-Salem, North Carolina, United States, 27103
  11. Orangeburg, South Carolina, United States, 29118
  12. San Antonio, Texas, United States, 78240

This information was found on the official FX-322 phase 2a study record page, which was recently updated to include these new study locations on Thursday, October 17, 2019.

MORE locations expected?

Could even more locations be added to this phase 2a study?

It’s possible.

However, based on the study’s estimated enrollment — limited to 96 participants — it seems unnecessary.

And what about FX-322 trials outside of the United States? Nothing to report yet. (That will be the topic of a separate post.)

Recruitment Status: Recruiting

As of Saturday, October 19, 2019, all 12 of the study locations listed above are now recruiting participants.

Frequency Therapeutics Commences Dosing in its Phase 2a Study of FX-322 for Sensorineural Hearing Loss; FDA Grants FX-322 Fast Track Designation

October 10, 2019

https://www.biospace.com/article/releases/frequency-therapeutics-commences-dosing-in-its-phase-2a-study-of-fx-322-for-sensorineural-hearing-loss-fda-grants-fx-322-fast-track-designation/

Frequency Therapeutics Commences Dosing in its Phase 2a Study of FX-322 for Sensorineural Hearing Loss; FDA Grants FX-322 Fast Track Designation

Frequency Therapeutics Begins Recruiting for Phase 2 Study of FX-322 in Patients with Sensorineural Hearing Loss

October 9, 2019

Frequency Therapeutics is now recruiting patients for phase 2 of its clinical trial of FX-322 in patients with sensorineural hearing loss.

This phase 2a study will assess the exploratory efficacy, as well as the local and systemic safety of single and repeat intratympanic doses of FX-322 compared to placebo in approximately 96 subjects with stable mild to moderately severe sensorineural hearing loss, with a medical history consistent with either excessive noise exposure or idiopathic sudden sensorineural hearing loss.

The study was added and updated to ClinicalTrials.gov on October 9, 2019.

There IS a placebo group… and…

Estimated enrollment is 96 participants and the first recruiting location is North Carolina.

The study is titled FX-322 in Adults With Stable Sensorineural Hearing Loss and can be found on ClinicalTrials.gov at this link: https://clinicaltrials.gov/ct2/show/NCT04120116?type=Intr&cond=Hearing+Loss&lupd_s=09%2F25%2F2019&lupd_d=14&sort=nwst

AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

October 1, 2019

https://finance.yahoo.com/news/agtc-otonomy-announce-strategic-collaboration-113000562.html

AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

A new study has identified 44 genes linked to age-related hearing loss giving a much clearer understanding of how the condition develops and potential treatments

September 26, 2019

https://www.sciencedaily.com/releases/2019/09/190926073350.htm

Signs of Improved Hearing With Progenitor Cell Activator (FX-322)

September 18, 2019

https://www.medpagetoday.com/meetingcoverage/aaohnsf/82242

Signs of Improved Hearing With Progenitor Cell Activator
Some pure tone improvement, significant increases in word recognition

https://journals.sagepub.com/doi/full/10.1177/0194599819858141f

Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss

September 17, 2019

http://investors.otonomy.com/news-releases/news-release-details/otonomy-initiating-phase-12-clinical-trial-oto-413-hearing-loss

Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss
Results expected in second half of 2020

WSJ: Cures for Hearing Loss May Be Found in New Drugs

September 15, 2019

https://www.wsj.com/articles/cures-for-hearing-loss-may-be-found-in-new-drugs-11568599440

Cures for Hearing Loss May Be Found in New Drugs

Researchers are trying to counter the biological causes of hearing loss—rather than just treating the effects

Akouos Launches The Sing Registry to Inform Future Therapeutic Development for Genetic Sensorineural Hearing Loss

September 13, 2019

https://www.businesswire.com/news/home/20190913005035/en/Akouos-Launches-Sing-Registry-Inform-Future-Therapeutic

Akouos Launches The Sing Registry to Inform Future Therapeutic Development for Genetic Sensorineural Hearing Loss

Akouos Discloses Lead Program, AK-OTOF, a Potential Gene Therapy for Sensorineural Hearing Loss

September 12, 2019

https://www.businesswire.com/news/home/20190912005094/en/Akouos-Discloses-Lead-Program-AK-OTOF-Potential-Gene

Akouos Discloses Lead Program, AK-OTOF, a Potential Gene Therapy for Sensorineural Hearing Loss

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001 for SSNHL

September 12, 2019

https://finance.yahoo.com/news/strekin-ag-announces-completion-patient-061500086.html

https://www.strekin.com/images/Press/20190911-Strekin-PR-recruitment-E.pdf

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Frequency Therapeutics Plans IPO for Hearing Loss Drug

September 7, 2019

https://xconomy.com/boston/2019/09/06/frequency-plans-ipo-for-hearing-loss-drug-more-regenerative-meds/

Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds

Strekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss and to Prepare NDA Filing in Europe

September 3, 2019

https://www.wdrb.com/news/national/strekin-ag-secures-financing-to-complete-development-of-str-in/article_e72a63e6-c808-57a8-9463-c5aea14c766e.html

Strekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss and to Prepare NDA Filing in Europe

Researchers find proteins that might restore damaged sound-detecting cells in the ear

August 5, 2019

https://www.sciencedaily.com/releases/2019/08/190805101127.htm

Researchers find proteins that might restore damaged sound-detecting cells in the ear
Date:
August 5, 2019
Source:
Johns Hopkins Medicine
Summary:
Using genetic tools in mice, researchers say they have identified a pair of proteins that precisely control when sound-detecting cells, known as hair cells, are born in the mammalian inner ear. The proteins may hold a key to future therapies to restore hearing in people with irreversible deafness.

Investor dollars flow to Frequency Therapeutics as company prepares to advance lead clinical candidate, FX-322, into Phase 2a study of sensorineural hearing loss

July 23, 2019

https://www.frequencytx.com/news-events/news-events-press-release-07-23-2019.php

Investor dollars flow to Frequency Therapeutics as company prepares to advance lead clinical candidate, FX-322, into Phase 2a study of sensorineural hearing loss, a condition for which there are no approved therapies…

Research Spotlight: Avenanthramide-C (AVN-C) prevents noise- and drug-induced hearing loss while protecting auditory hair cells from oxidative stress

July 21, 2019

https://www.nature.com/articles/s41420-019-0195-1

https://www.ncbi.nlm.nih.gov/pubmed/31312524?dopt=Abstract

Avenanthramide-C prevents noise- and drug-induced hearing loss while protecting auditory hair cells from oxidative stress.

Cell Death Discov. 2019;5:115

Authors: Umugire A, Lee S, Kim D, Choi M, Kim HS, Cho HH

Abstract

Noise exposure or ototoxic drugs instigate various types of damage to the cochlea, resulting in hearing loss (HL). While the incidence of HL is growing continuously, there are, so far, no adequate drugs to prevent or treat HL. Avenanthramide (AVN), a natural product extracted from oats, has been reported to possess anti-oxidant/inflammatory properties, and protect several types of cells. In this study, we investigated whether AVN-C can protect auditory hair cells, and preserve hearing from noise trauma and ototoxic drugs. Wild-type C57BL/6 mice were used to generate several HL models. Serum and perilymphatic fluid samples were analyzed using mass spectrophotometry to detect AVN-C. AVN-C crossed the blood-labyrinth barrier, and was detected in the perilymph after systemic injection. Pretreatment by AVN-C 24โ€‰h before exposure to temporary threshold shift noise contributed to the preserving hearing. Moreover, in the case of permanent threshold shift, AVN-C provided significant protection from noise. AVN-C also strongly protected against deterioration in hearing due to kanamycin and furosemide (Kโ€‰+โ€‰F). According to the results of our scanning electron microscopy analysis, many outer hair cells (OHCs) were destroyed by noise trauma, while AVN-C prevented these losses. OHC loss due to Kโ€‰+โ€‰F was even more severe, even affecting the apex. Strikingly, AVN-C treatment maintained OHCs at a level comparable to normal cochlea. AVN-C reduced the dichlorofluorescin (DCF)-positive population in gentamicin-treated HEI-OC1 in vitro. The expressions of TNF-a, BAK, IL-1b, and Bcl-2 were attenuated by AVN-C, revealing its antioxidant effects. The results of this study show that AVN-C crosses the blood-labyrinth barrier and provide a significant protection against noise- and drug-induced ototoxicity. Hence, AVN-C is a good candidate for future therapy aimed at protecting against sensorineural HL.

PMID: 31312524 [PubMed]

Astellas picks up Frequency’s regenerative hearing loss med FX-322 outside U.S. for $80M

July 17, 2019

https://www.fiercebiotech.com/biotech/astellas-picks-up-frequency-s-regenerative-hearing-loss-med-outside-u-s-for-80m

Astellas Adds To Regenerative Medicine Portfolio In Hearing Loss Deal With Frequency Therapeutics [Note: Paywall]

July 17, 2019

https://scrip.pharmaintelligence.informa.com/SC125552/Astellas-Adds-To-Regenerative-Medicine-Portfolio-In-Hearing-Loss-Deal-With-Frequency

Astellas Adds To Regenerative Medicine Portfolio In Hearing Loss Deal With Frequency

Sensorion Receives FDA IND Approval for Arazasetron (SENS-401) for the Treatment of Sudden Sensorineural Hearing Loss (SSNHL)

July 12, 2019

https://finance.yahoo.com/news/sensorion-receives-fda-ind-approval-053000700.html

Sensorion Receives FDA IND Approval for Arazasetron (SENS-401)

New research shows that different types of hearing loss are best treated by specially tailored solutions

July 9, 2019

https://interestingengineering.com/research-highlights-different-types-of-hearing-loss-and-need-for-new-unique-treatments

Research Highlights Different Types of Hearing Loss And Need for New Unique Treatments
New research shows that different types of hearing loss are best treated by specially tailored solutions.

Inner Ear Drug Delivery: Tomorrow’s Treatment for Hearing Loss?

July 4, 2019

https://journals.lww.com/thehearingjournal/Fulltext/2019/07000/Inner_Ear_Drug_Delivery__Tomorrow_s_Treatment_for.1.aspx

Inner Ear Drug Delivery
Tomorrow’s Treatment for Hearing Loss?

Optimized gene-editing system halts hearing loss in mice with hereditary deafness

July 3, 2019

Single letter speaks volumes

Optimized gene-editing system halts hearing loss in mice with hereditary deafness

Radical cure for deafness may have been found thanks to lab animals: Scientists revealed that hearing has been salvaged in mice by ‘snipping’ a mutation out of their DNA

July 3, 2019

https://www.thelondoneconomic.com/lifestyle/health/radical-cure-for-deafness-may-have-been-found-thanks-to-lab-animals/03/07/

Radical cure for deafness may have been found thanks to lab animals
Scientists revealed that hearing has been salvaged in mice by ‘snipping’ a mutation out of their DNA.

Sound Pharmaceuticals announces positive topline results from SPI-1005 Phase 2b clinical trial… clinically relevant improvements in sensorineural hearing loss… 65% and 95% over placebo at 8 weeks…

June 25, 2019

https://finance.yahoo.com/news/sound-pharmaceuticals-announces-positive-topline-130000754.html

Sound Pharmaceuticals announces positive topline results from SPI-1005 Phase 2b clinical trial… clinically relevant improvements in sensorineural hearing loss… 65% over placebo at 8 weeks

Daewoong to develop hearing loss treatment using ion-channel platform tech

June 14, 2019

http://www.koreabiomed.com/news/articleView.html?idxno=5927

Daewoong to develop hearing loss treatment using ion-channel platform tech

Triamcinolone a Safe and Efficacious Treatment Option for Idiopathic Sudden Sensorineural Hearing Loss, Study Says

June 14, 2019

https://www.ncbi.nlm.nih.gov/pubmed/31192900?dopt=Abstract

https://journals.lww.com/otology-neurotology/Abstract/2019/07000/Intratympanic_Triamcinolone_Acetonide_as_Treatment.4.aspx

Intratympanic Triamcinolone Acetonide as Treatment Option for Idiopathic Sudden Sensorineural Hearing Loss.

Otol Neurotol. 2019 Jul;40(6):720-727

Authors: Dahm V, Nieratschker M, Riss D, Kaider A, Auinger A, Honeder C, Arnoldner C

Abstract

INTRODUCTION: Corticosteroids represent the most commonly used treatment option for patients with idiopathic sudden sensorineural hearing loss. In the past, these compounds were mainly formulated and tested for intravenous or oral administration. Intratympanic application is increasingly being used, often as salvage treatment. The most suitable corticosteroid for local application has yet to be identified. Trials have suggested that triamcinolone acetonide has superior molecular properties for this treatment modality.

METHODS: The main aim of this study was to retrospectively assess the first audiometric results of patients diagnosed with idiopathic sudden sensorineural hearing loss and treated simultaneously with systemic prednisolone and intratympanic triamcinolone acetonide. This data was then compared to systemic treatment only, as well as to historic cohorts treated intratympanically with widely used corticosteroids, namely dexamethasone or methylprednisolone.

RESULTS: 90 patients received intravenous prednisolone only, and 89 individuals underwent intravenous treatment combined with three to four simultaneous intratympanic applications of triamcinolone. Eight patients received intratympanic triamcinolone as first-line treatment. After adjusting data for sex, time since onset, age, and severity of hearing loss, no statistically significant difference between the two main treatment groups could be identified. No major adverse events were observed, specifically no otitis media or persistent vertigo. Two perforated tympanic membranes healed spontaneously within several days.

CONCLUSION: While the exact role of intratympanic injections requires additional trials, triamcinolone resulted in similar outcomes compared to studies using dexamethasone or methylprednisolone. Due to favorable pharmacological properties, triamcinolone represents a safe and efficacious alternative for intratympanic treatment in idiopathic sensorineural hearing loss.

PMID: 31192900 [PubMed – in process]

Drug to treat malaria could mitigate hereditary hearing loss

June 11, 2019

https://www.sciencedaily.com/releases/2019/06/190611133953.htm

Drug to treat malaria could mitigate hereditary hearing loss

Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing Loss

May 27, 2019

https://www.apnews.com/Business%20Wire/d2f0d4c0a9864ab795c75f837f1792b0

Rinri Therapeutics Secures £1.4 Million Seed Funding to Advance Its Novel Regenerative Cell Therapy to Treat Sensorineural Hearing Loss

May 20, 2019

https://finance.yahoo.com/news/rinri-therapeutics-secures-1-4-060000946.html

Novartis begins recruiting patients with hearing loss for Phase 2 (Part C) of inner ear gene therapy [CGF166] trial

May 13, 2019

https://clinicaltrials.gov/ct2/show/NCT02132130?type=Intr

Frequency’s FX-322 improves hearing function in trial subjects

April 10, 2019

https://www.drugdevelopment-technology.com/news/frequency-fx-322-hearing-restoration-data/

Biotech Frequency shows early positive results for small-molecule hearing loss therapy

April 9, 2019

https://www.fiercebiotech.com/biotech/frequency-shows-early-positive-results-for-small-molecule-hearing-loss-therapy

Drug being tested in London could be breakthrough in treating hearing loss

March 6, 2019

https://www.standard.co.uk/news/health/drug-being-tested-in-london-could-be-breakthrough-in-treating-hearing-loss-a4083811.html

Local company working on treatment to reverse hearing loss

March 1, 2019

https://www.wcvb.com/article/local-company-working-on-treatment-to-reverse-hearing-loss/26596728

Scientists used gene therapy to cure deafness in mice

February 20, 2019

https://futurism.com/the-byte/gene-therapy-deafness-mice

SCIENTISTS USED GENE THERAPY TO CURE DEAFNESS IN MICE

Audion Therapeutics and REGAIN Consortium Announce Positive Results from Phase I Study of Notch Inhibitor LY3056480 in Patients with Sensorineural Hearing Loss

February 5, 2019

https://www.b3cnewswire.com/201902051883/audion-therapeutics-and-regain-consortium-announce-positive-phase-i-results-in-patients-with-sensorineural-hearing-loss.html

AudioCure Pharma’s AC102 receives EMA orphan drug designation for the treatment of sudden sensorineural hearing loss (SSNHL)

January 29, 2019

https://www.biospace.com/article/releases/audiocure-pharma-s-ac102-receives-ema-orphan-drug-designation-for-the-treatment-of-sudden-sensorineural-hearing-loss-ssnhl-/

Melbourne researchers flag potential for new hearing loss treatment using nanoparticles

November 8, 2018

https://www.abc.net.au/news/2018-11-08/nanoparticle-treatment-possible-for-common-form-of-hearing-loss/10477498

Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss

November 6, 2018

http://investors.otonomy.com/news-releases/news-release-details/otonomy-presents-data-highlighting-potential-oto-413-otic

Study points to possible new therapy for hearing loss

October 15, 2018

https://medicalxpress.com/news/2018-10-therapy-loss.html

Cochlear neuron discovery could yield new treatments for hearing loss

September 13, 2018

https://www.fiercebiotech.com/research/cochlear-neuron-discovery-could-mean-new-treatments-for-hearing-loss

Cochlear neuron discovery could yield new treatments for hearing loss

Cochlear hair cell regeneration: an emerging opportunity to cure noise-induced sensorineural hearing loss

May 4, 2018

https://www.sciencedirect.com/science/article/abs/pii/S1359644617303173?via%3Dihub

https://pubmed.ncbi.nlm.nih.gov/29733894/

Cochlear hair cell regeneration: an emerging opportunity to cure noise-induced sensorineural hearing loss
Author links open overlay panelIbrahimaYoumWeiLi
https://doi.org/10.1016/j.drudis.2018.05.001

  • « Go to Previous Page
  • Page 1
  • Page 2

Powered by Urgent Research

Copyright © 2025 Urgent Research